TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04445298

Intervention type: DIAGNOSTIC_TEST
Intervention: Transepidermal water loss
Description: We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transepidermal water loss
Description: We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin tape stripping
Description: Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin tape stripping
Description: Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin tape stripping
Description: Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin tape stripping
Description: Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
Study: NCT00616447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: 6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: placebo sham
Description: Sham treatment will mimic active treatment mentioned above.
Study: NCT03051438

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subxiphoid uniportal VATS
Description: Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
Study: NCT04445298

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial PCR swab
Description: Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial PCR swab
Description: Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial PCR swab
Description: Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial PCR swab
Description: Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
Study: NCT02723097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 RP
Study: NCT00500032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood draw
Description: Blood draw from subjects previously vaccinated in 6108A1-500 trial
Study: NCT00349466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: Orally CF101 1mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally matching Placebo
Study: NCT02358668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTI320
Description: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTI320
Description: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
Study: NCT03051438

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Three-port VATS
Description: The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
Study: NCT02358668

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BTI320 matching placebo
Description: Placebo
Study: NCT00234598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing only
Description: Toothbrushing three times per 24 hours without chlorhexidine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine only
Description: Chlorhexidine oral rinse twice per 24 hours without toothbrushing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing and Chlorhexidine
Description: Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
Study: NCT02366143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Study: NCT02419417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986158
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT02592213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell-assisted lipotransfer
Description: Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
Study: NCT01149122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/Oxaliplatin
Description: GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)
Description: GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
Study: NCT04253938

Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.
Study: NCT04331483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: Supervised sessions of at least 15 minutes 4 times a Week combined with unsupervised sessions.~The supervised activities include moderate-intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient can also do unsupervised sessions, autonomously, on the bike thanks to a smartphone application developed by the Kiplin company, with challenges to be carried out by teams of 2 to 5 people (team including several patients, possibility to include relatives) over periods of 1 to 3 weeks per challenge.
Study: NCT00043069

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Study: NCT00914498

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local, pre-incisional injection of 20 ml 1% xylocaine
Description: Local, pre-incisional injection of 20 ml 1% xylocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local, pre-incisional injection of 20 ml 1% xylocaine
Description: Local, pre-incisional injection of 20 ml 1% xylocaine
Study: NCT03928379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT00043069

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen Antagonists

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Antagonists

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estrogen Antagonists

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Antagonists

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate sodium

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02364596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood for immunogenicity will be collected from all subjects at various timepoints.
Study: NCT00663975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCI 1020
Description: capsules (4,000 units of lipase) will be administered with meals and snacks
Study: NCT05230719

Intervention type: PROCEDURE
Intervention: Radial Artery Approach
Description: dTRA or conventional TRA for radical artery approach

Intervention type: PROCEDURE
Intervention: Radial Artery Approach
Description: dTRA or conventional TRA for radical artery approach
Study: NCT01536587

Intervention type: DRUG
Group type: OTHER
Intervention: Salmeterol
Description: At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
Study: NCT04435964

Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
Study: NCT05614440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic + tramadol hydrochloride
Description: Using tramadol hydrochloride and articain HCL for inferior alveolar nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Only local anesthetic
Description: Using articain HCL for inferior alveolar nerve block
Study: NCT01109511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Study: NCT00068432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
Study: NCT02867683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrotactile Feedback
Description: Balance training Vibrotactile feedback applied to the trunk
Study: NCT00645177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-869
Description: 0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: 90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-869
Description: 0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
Study: NCT03715777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium botulinum type A (BoNTA)
Description: Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:
Study: NCT00771940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Solvent, cont. infusion
Study: NCT01556997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 985
Description: PERa/AMLb capsule taken once daily by mouth for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate
Description: AMLb capsule taken once daily by mouth for six weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Erbumine
Description: PERe capsule taken once daily by mouth for six weeks
Study: NCT00734461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone
Study: NCT02695862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Study: NCT04146857

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia
Description: Nap in hypoxia chamber at 20.9% oxygen (36 m asl)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia 1
Description: Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia 2
Description: Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
Study: NCT06331975

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Radiomic signature
Description: Assessment of radiomic signature and tumor genetic profile in patients with Non Small Cell Lung Cancer (NSCLC)
Study: NCT03465709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Study Drug
Study: NCT04398329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-034
Description: HTX-034, low dose
Study: NCT00893139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution 0.05%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution 0.10%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-38583 vehicle
Description: Inactive ingredients used as a placebo comparator
Study: NCT02088398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Study: NCT01482234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXT Me
Description: text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXT Me
Description: text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXT Me
Description: text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
Study: NCT03696199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Local Anesthesia
Description: The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia
Description: 0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
Study: NCT04398329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-034
Description: HTX-034, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-034
Description: HTX-034, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-034
Description: HTX-034, high dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl, 50 mg